The chemiluminescence based Ziplex® automated workstation focus array reproduces ovarian cancer Affymetrix GeneChip® expression profiles
暂无分享,去创建一个
Anne-Marie Mes-Masson | A. Mes-Masson | D. Provencher | P. Tonin | M. Quinn | David Englert | Daniel J. Wilson | Diane Provencher | Patricia N Tonin | A. Birch | S. L. Arcand | Michael CJ Quinn | Suzanna L Arcand | P. Wojnarowicz | Daniel J Wilson | Fiona Young | Adam A Dempsey | Ashley H Birch | Paulina M Wojnarowicz | David Englert | A. Dempsey | Fiona Young
[1] R. Bernards,et al. Enabling personalized cancer medicine through analysis of gene-expression patterns , 2008, Nature.
[2] Anne-Marie Mes-Masson,et al. Signature of a silent killer: expression profiling in epithelial ovarian cancer , 2004, Expert review of molecular diagnostics.
[3] Anil Potti,et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] V. Livolsi,et al. Gene expression profiling of human ovarian tumours , 2006, British Journal of Cancer.
[5] A. Mes-Masson,et al. Reprogramming of the transcriptome in a novel chromosome 3 transfer tumor suppressor ovarian cancer cell line model affected molecular networks that are characteristic of ovarian cancer , 2009, Molecular carcinogenesis.
[6] A. Mes-Masson,et al. Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes , 2008, Molecular carcinogenesis.
[7] Crispin J. Miller,et al. Cell Culture , 2010, Cell.
[8] D. Altman,et al. STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.
[9] M. Moses,et al. Ovarian cancer biomarkers: current options and future promise. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.
[10] T. Hudson,et al. From gene profiling to diagnostic markers: IL‐18 and FGF‐2 complement CA125 as serum‐based markers in epithelial ovarian cancer , 2006, International journal of cancer.
[11] E. D. de Vries,et al. Molecular prognostic markers in ovarian cancer: toward patient‐tailored therapy , 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
[12] A. Mes-Masson,et al. Construction of a chromosome 17 transcriptome in serous ovarian cancer identifies differentially expressed genes , 2007, International Journal of Gynecologic Cancer.
[13] T. Hudson,et al. Characterization of variability in large-scale gene expression data: implications for study design. , 2002, Genomics.
[14] A. Ullrich,et al. ErbB-3 predicts survival in ovarian cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Cannistra,et al. Gene-expression profiling in epithelial ovarian cancer , 2008, Nature Clinical Practice Oncology.
[16] K. Partheen,et al. Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas , 2008, International journal of cancer.
[17] T. Hudson,et al. Global analysis of chromosome X gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines. , 2007, International journal of oncology.
[18] Anne-Marie Mes-Masson,et al. Microarray analysis of gene expression mirrors the biology of an ovarian cancer model , 2001, Oncogene.
[19] James J. Chen,et al. Reproducibility of microarray data: a further analysis of microarray quality control (MAQC) data , 2007, BMC Bioinformatics.
[20] Cherie Blenkiron,et al. Identification of clinically relevant genes on chromosome 11 in a functional model of ovarian cancer tumor suppression. , 2003, Cancer research.
[21] 榎本 明美,et al. What's going on 婦人科癌 Gene expression signature with independent prognostic significance in epithelial ovarian cancer. Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, Libermann TA, Cannistra SA. J Clin Oncol. 2004; 22: 4700-10. PMID: 15505275--上皮性卵巣癌における遺伝子発現特性は、独立した予後因子である , 2005 .
[22] R. Agarwal,et al. Expression profiling and individualisation of treatment for ovarian cancer. , 2006, Current opinion in pharmacology.
[23] S. Minkin,et al. High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. , 2005, Neoplasia.
[24] S. Calza,et al. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. , 2006, Gynecologic oncology.
[25] C. Le Page,et al. BTF4/BTNA3.2 and GCS as Candidate mRNA Prognostic Markers in Epithelial Ovarian Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.
[26] P. Collins,et al. Performance comparison of one-color and two-color platforms within the Microarray Quality Control (MAQC) project , 2006, Nature Biotechnology.
[27] Laurent Ozbun,et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. , 2008, Cancer research.
[28] T. Hudson,et al. Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines , 2003, Oncogene.
[29] T. Hudson,et al. Gene expression microarray analysis and genome databases facilitate the characterization of a chromosome 22 derived homogenously staining region , 2004, Molecular carcinogenesis.
[30] Maqc Consortium. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements , 2006, Nature Biotechnology.
[31] A. Mes-Masson,et al. Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p , 2007, Oncogene.
[32] Marie Joseph,et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.